Lucid Diagnostics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Lucid Diagnostics Stock Summary

Lucid Diagnostics competes with PAVmed, Neuropace, Hyperfine, Orthopediatrics Corp, and HCW Biologics. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.

Lucid Diagnostics Key Financial Ratios

Lucid Diagnostics Key Balance Sheet Accounts

Lucid Diagnostics Key Income Statement Accounts

Lucid Diagnostics Key Cash Accounts

Lucid Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lucid Diagnostics's current stock value. Our valuation model uses many indicators to compare Lucid Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lucid Diagnostics competition to find correlations between indicators driving Lucid Diagnostics's intrinsic value. More Info.Lucid Diagnostics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Lucid Diagnostics' Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lucid Diagnostics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Lucid Diagnostics Systematic Risk

Today, most investors in Lucid Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lucid Diagnostics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lucid Diagnostics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Lucid Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lucid Diagnostics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lucid Diagnostics based on widely used predictive technical indicators. In general, we focus on analyzing Lucid Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lucid Diagnostics's daily price indicators and compare them against related drivers.

When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.